$ARDS Aridis Pharmaceuticals Announces First Quart
Post# of 102954
(Total Views: 198)
Posted On: 06/08/2021 11:35:55 AM
$ARDS Aridis Pharmaceuticals Announces First Quarter 2021 Results
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.
First Quarter Highlights
Announced the addition of a second inhaled monoclonal antibody ("mAb"
to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021.
Announced the preclinical development services support of the company's COVID mAb program from NIAID and the Coronavirus Immunotherapy Consortium (CoVIC).
Licensed the CRISPR gene editing technology from the Broad Institute of MIT and Harvard. CRISPR is a component of the ʎPEXTM mAb discovery and production platform technology.
Entered into a ʎPEX out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans and potentially lead to a viral pandemic.
Continued enrolling global Phase 3 clinical trial of AR-301 in patients with ventilator associated pneumonia (VAP) including patients who presented with S. aureus VAP as a secondary infection to COVID-19. Interim futility analysis is expected in 2H 2021 and top-line data expected in 1H 2022.
Executed a registered direct offering with gross proceeds of approximately $8.5 million in the fourth quarter of 2020 and approximately $7.0 million in March 2021.
https://finance.yahoo.com/news/aridis-pharmac...00717.html
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.
First Quarter Highlights
Announced the addition of a second inhaled monoclonal antibody ("mAb"
to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021. Announced the preclinical development services support of the company's COVID mAb program from NIAID and the Coronavirus Immunotherapy Consortium (CoVIC).
Licensed the CRISPR gene editing technology from the Broad Institute of MIT and Harvard. CRISPR is a component of the ʎPEXTM mAb discovery and production platform technology.
Entered into a ʎPEX out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans and potentially lead to a viral pandemic.
Continued enrolling global Phase 3 clinical trial of AR-301 in patients with ventilator associated pneumonia (VAP) including patients who presented with S. aureus VAP as a secondary infection to COVID-19. Interim futility analysis is expected in 2H 2021 and top-line data expected in 1H 2022.
Executed a registered direct offering with gross proceeds of approximately $8.5 million in the fourth quarter of 2020 and approximately $7.0 million in March 2021.
https://finance.yahoo.com/news/aridis-pharmac...00717.html
(0)
(0)Scroll down for more posts ▼